<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05024318</url>
  </required_header>
  <id_info>
    <org_study_id>19/007</org_study_id>
    <nct_id>NCT05024318</nct_id>
  </id_info>
  <brief_title>NeoAdjuvant Pembrolizumab and STEreotactic Radiotherapy Prior to Nephrectomy for Renal Cell Carcinoma</brief_title>
  <acronym>NAPSTER</acronym>
  <official_title>NeoAdjuvant Pembrolizumab and STEreotactic Radiotherapy Prior to Nephrectomy for Renal Cell Carcinoma: Investigating Induced Immune Context Changes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peter MacCallum Cancer Centre, Australia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peter MacCallum Cancer Centre, Australia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, open label, phase II, randomised, non-comparative clinical trial,&#xD;
      evaluating changes in tumour-responsive T-cells following neoadjuvant stereotactic ablative&#xD;
      body radiotherapy (SABR) with or without pembrolizumab, prior to nephrectomy, in patients&#xD;
      with localised primary clear cell renal cell carcinoma (ccRCC).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mPR post-SABR with or without pembrolizumab</measure>
    <time_frame>At nephrectomy performed 9-12 weeks after first dose of pembrolizumab</time_frame>
    <description>The mPR rate is defined as &lt;10% residual tumour at post-nephrectomy specimens</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CD8+ TRM in baseline biopsy and post-nephrectomy specimen, all measured as a continuous variable.</measure>
    <time_frame>Baseline and at nephrectomy performed 9-12 weeks after first dose of pembrolizumab</time_frame>
    <description>To describe changes in tumour-responsive T-cells, TRM CD8+ T-cells from baseline to post-nephrectomy in patients treated with SABR with or without pembrolizumab treatment followed by nephrectomy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TCF-1 + tumour infiltrating lymphocytes (TILs) in baseline biopsy and post-nephrectomy specimen, measured as a continuous variable</measure>
    <time_frame>Baseline and at nephrectomy performed 9-12 weeks after first dose of pembrolizumab</time_frame>
    <description>To describe changes in TCF-1+ T-cells from baseline to post-nephrectomy in patients treated with SABR with or without pembrolizumab treatment followed by nephrectomy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune response cells in baseline biopsy and post-nephrectomy specimen</measure>
    <time_frame>Baseline and at nephrectomy performed 9-12 weeks after first dose of pembrolizumab</time_frame>
    <description>Change in immune response from baseline to post-nephrectomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The tumour-responsive TRM cells inclusive of CD4+ and CD8+ compartments</measure>
    <time_frame>2 weeks prior to nephrectomy</time_frame>
    <description>Percentage of tumour responsive T-cells (inclusive CD4/CD8) after neo-adjuvant treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of SABR with or without pembrolizumab in the neo-adjuvant setting</measure>
    <time_frame>60 days post nephrectomy</time_frame>
    <description>Adverse events, as measured by CTCAE v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in immune response associated with mPR</measure>
    <time_frame>Baseline and at nephrectomy performed 9-12 weeks after first dose of pembrolizumab</time_frame>
    <description>Immune response cells in baseline biopsy and post-nephrectomy specimens</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PD-L1 and PD-L2 expression in tumour</measure>
    <time_frame>Baseline and at nephrectomy performed 9-12 weeks after first dose of pembrolizumab</time_frame>
    <description>PD-L1 and PD-L2 expression in baseline biopsy and post-nephrectomy specimens</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Radiological features including contrast enhancement consistent with mPR</measure>
    <time_frame>2 weeks prior to nephrectomy</time_frame>
    <description>Post treatment radiological features including contrast enhancement</description>
  </other_outcome>
  <other_outcome>
    <measure>Radiological features including size reduction consistent with mPR</measure>
    <time_frame>2 weeks prior to nephrectomy</time_frame>
    <description>Post treatment radiological features including size reduction</description>
  </other_outcome>
  <other_outcome>
    <measure>Radiological features including maximum tumour diameter consistent with mPR</measure>
    <time_frame>2 weeks prior to nephrectomy</time_frame>
    <description>Post treatment radiological features including maximum tumour diameter</description>
  </other_outcome>
  <other_outcome>
    <measure>Radiological features including margins consistent with mPR</measure>
    <time_frame>2 weeks prior to nephrectomy</time_frame>
    <description>Post treatment radiological features including margins</description>
  </other_outcome>
  <other_outcome>
    <measure>Baseline versus post-nephrectomy tissue for immune context changes</measure>
    <time_frame>Baseline and at nephrectomy performed 9-12 weeks after first dose of pembrolizumab</time_frame>
    <description>To investigate baseline versus post-nephrectomy tissue for immune context changes, using a broad panel of assays which will be further developed through the lifetime of the study</description>
  </other_outcome>
  <other_outcome>
    <measure>Baseline versus post-nephrectomy tissue immune network signalling</measure>
    <time_frame>Baseline and at nephrectomy performed 9-12 weeks after first dose of pembrolizumab</time_frame>
    <description>Baseline and post-nephrectomy immune network signalling , using a broad panel of assays which will be further developed through the lifetime of the study</description>
  </other_outcome>
  <other_outcome>
    <measure>Systemic immune cells in baseline and post-nephrectomy blood samples</measure>
    <time_frame>Baseline and at nephrectomy performed 9-12 weeks after first dose of pembrolizumab</time_frame>
    <description>To investigate changes in systemic immunity of patients with primary ccRCC treated with SABR with or without pembrolizumab</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Renal Cell Carcinoma, Clear Cell, Somatic</condition>
  <arm_group>
    <arm_group_label>SABR plus nephrectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stereotactic Ablative Radiotherapy (SABR) will be prescribed to a dose of 42Gy in 3 fractions. All radiotherapy treatment be completed within 3 weeks.Patients will undergo nephrectomy within 9-12 weeks after the first dose of treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pembrolizumab followed by SABR after cycle 1 plus nephrectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pembrolizumab 200 mg (flat dose) will be administered as a 30 minute IV infusion every 21 days for 3 cycles. Patients will receive 1 cycle of pembolizumab prior to SABR followed by an additional 2 cycles of pembrolizumab (1 cycle is 21 days). Patients will undergo nephrectomy 9-12 weeks after commencement of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab 200 mg tobe administered as a 30 minute IV infusion every 21 days for 3 cycles</description>
    <arm_group_label>Pembrolizumab followed by SABR after cycle 1 plus nephrectomy</arm_group_label>
    <other_name>MK-3475</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Ablative Radiotherapy</intervention_name>
    <description>42Gy delivered in 3 fractions</description>
    <arm_group_label>Pembrolizumab followed by SABR after cycle 1 plus nephrectomy</arm_group_label>
    <arm_group_label>SABR plus nephrectomy</arm_group_label>
    <other_name>SABR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Nephrectomy</intervention_name>
    <description>Partial or total nephrectomy performed 9-12 weeks after first dose of Pembrolizumab</description>
    <arm_group_label>Pembrolizumab followed by SABR after cycle 1 plus nephrectomy</arm_group_label>
    <arm_group_label>SABR plus nephrectomy</arm_group_label>
    <other_name>Surgical removal of a kidney</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient has provided written informed consent&#xD;
&#xD;
          2. Male or female aged 18 years or older at written informed consent&#xD;
&#xD;
          3. Histologically or cytologically confirmed diagnosis of RCC with clear cell, rhabdoid&#xD;
             or sarcomatoid components&#xD;
&#xD;
          4. Tumour stage T1B-T3, N0 or N1, M0 or low volume M1 planned for nephrectomy&#xD;
&#xD;
          5. Patients must have adequate bone marrow, hepatic and renal function documented within&#xD;
             14 days prior to randomisation:&#xD;
&#xD;
               -  White Blood Cell (WBC) ≥ 3 X 10^9/L&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥1.5 X 10^9/L&#xD;
&#xD;
               -  Platelets ≥ 100 X 10^9/L&#xD;
&#xD;
               -  Haemoglobin ≥ 100 g/L independent of transfusion&#xD;
&#xD;
               -  Serum Creatinine ≤1.5 X Upper Limit of Normal (ULN) or measured or calculated&#xD;
                  CrCl calculated as per institutional standard ≥ 30 ml/min. GFR can also be used&#xD;
                  in place of serum creatinine or CrCl.&#xD;
&#xD;
               -  Total bilirubin ≤1.5 X ULN except for patients with known Gilbert's Syndrome&#xD;
&#xD;
               -  Albumin &gt; 30 g/L&#xD;
&#xD;
               -  AST and ALT ≤1.5 X ULN&#xD;
&#xD;
               -  INR or PT ≤1.5 X ULN unless patient is receiving anticoagulant therapy&#xD;
&#xD;
          6. ECOG performance status of 0 or 1&#xD;
&#xD;
          7. Women of child birth potential (WOCBP) must have a negative urine or serum pregnancy&#xD;
             test within 72 hours prior to randomisation. If the urine test is positive or cannot&#xD;
             be confirmed as negative, a serum pregnancy test will be required&#xD;
&#xD;
          8. WOCBP should be willing to use two methods of birth control, or be surgically sterile,&#xD;
             or abstain from heterosexual activity for the course of the study through 120 days&#xD;
             after the last dose of study medication. Patients of childbearing potential are those&#xD;
             who have not been surgically sterilised or have not been free from menses for more&#xD;
             than 1 year&#xD;
&#xD;
          9. Male patients should agree to use an adequate method of contraception starting with&#xD;
             the first dose of study therapy through 120 days after the last dose of study therapy&#xD;
&#xD;
         10. Patient agrees to the collection and use of their fresh tumour samples and peripheral&#xD;
             blood for translational research&#xD;
&#xD;
         11. Patient is willing and able to comply with the protocol for the duration of the study&#xD;
             including undergoing biopsies, treatment, and scheduled visits and examination&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Had prior treatment with any anti-PD-1, or anti-PD-L1, or PD-L2 agent or with an&#xD;
             antibody targeting any other immune-regulatory receptors or mechanisms. Examples of&#xD;
             such antibodies include antibodies against IDO, PD-L1, IL-2R, and GITR&#xD;
&#xD;
          2. Known or active inflammatory bowel disease involving colon and small bowels&#xD;
&#xD;
          3. Previous radiotherapy to the upper abdomen with radiation dose overlap to the involved&#xD;
             kidney&#xD;
&#xD;
          4. Is currently participating in or has participated in a study of an investigational&#xD;
             agent or has used an investigational device within 4 weeks prior to randomisation&#xD;
&#xD;
          5. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy&#xD;
             exceeding 10 mg daily dose of prednisone or equivalent or any other form of&#xD;
             immunosuppressive therapy within 7 days prior to randomisation&#xD;
&#xD;
          6. Has an active autoimmune disease that has required systemic treatment in the last 2&#xD;
             years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive&#xD;
             drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid&#xD;
             replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a&#xD;
             form of systemic treatment and is allowed&#xD;
&#xD;
          7. Has a known additional malignancy that is progressing or has required active treatment&#xD;
             in the last 3 years Note: Basal cell carcinoma of the skin, squamous cell carcinoma of&#xD;
             the skin, superficial bladder cancer, or carcinoma in situ, such as breast cancer in&#xD;
             situ, that has undergone potentially curative therapy are not excluded&#xD;
&#xD;
          8. Has known active CNS metastases and/or carcinomatous meningitis. Patients with&#xD;
             previously treated brain metastases may participate provided they are radiologically&#xD;
             stable, i.e. without evidence of progression for at least 4 weeks by repeat imaging&#xD;
             (note that the repeat imaging should be performed during study screening), clinically&#xD;
             stable and without requirement of steroid treatment for at least 14 days prior to&#xD;
             randomisation&#xD;
&#xD;
          9. Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients&#xD;
&#xD;
         10. Has a history of (non-infectious) pneumonitis that required steroids or has current&#xD;
             pneumonitis&#xD;
&#xD;
         11. Has an active infection requiring systemic therapy&#xD;
&#xD;
         12. Has a known history of HIV infection&#xD;
&#xD;
         13. Has known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg]&#xD;
             reactive)or known active Hepatitis C (defined as HCV RNA [qualitative] is detected)&#xD;
             infection&#xD;
&#xD;
         14. Has a history or current evidence of any condition, therapy, or laboratory abnormality&#xD;
             that might confound the results of the study, interfere with the patient's&#xD;
             participation for the full duration of the study, or is not in the best interest of&#xD;
             the patient to participate, in the opinion of the treating investigator&#xD;
&#xD;
         15. Has a known psychiatric or substance abuse disorders that would interfere with&#xD;
             cooperation with the requirements of the trial&#xD;
&#xD;
         16. Has received a live virus vaccine within 30 days prior to randomisation. Examples of&#xD;
             live vaccines include, but are not limited to, the following: measles, mumps, rubella,&#xD;
             varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG),&#xD;
             and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed&#xD;
             virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®)&#xD;
             are live attenuated vaccines and are not allowed&#xD;
&#xD;
         17. Has had a prior solid organ transplant&#xD;
&#xD;
         18. Is pregnant or breastfeeding, or expecting to conceive or father children within the&#xD;
             projected duration of the study, starting with the screening visit through 120 days&#xD;
             after the last dose of study drug.&#xD;
&#xD;
         19. Any contraindications for surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shankar Siva, A/Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Peter MacCallum Cancer Centre, Australia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shankar Siva, A/Prof</last_name>
    <phone>+61 3 8559 7988</phone>
    <email>Shankar.Siva@petermac.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Arun Azad, A/Prof</last_name>
    <phone>+61 3 8559 7165</phone>
    <email>Arun.Azad@petermac.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Shankar Siva, A/Prof</last_name>
      <phone>+61 3 8559 7988</phone>
      <email>Shankar.Siva@petermac.org</email>
    </contact>
    <contact_backup>
      <last_name>Arun Azad, A/Prof</last_name>
      <phone>+61 3 8559 7165</phone>
      <email>Arun.Azad@petermac.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 29, 2021</study_first_submitted>
  <study_first_submitted_qc>August 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

